Obagi的新填充者表现良好,Juvéderm Voluma在恢复中半部时表现良好,安全和满意度很高,其头皮血清显示早期毛发的好处。 Obagi's new filler performed as well as Juvéderm Voluma in midface restoration, with high safety and satisfaction, and its scalp serum showed early hair benefits.

在2025年美国皮肤外科协会会议上,Obagi Medical 提出了新的临床数据,显示其Obagi® saypha® ChIQTM 氨酸填充剂在恢复中脸体积和改善鼻皮方面表现与Juvéderm Voluma® XC一样,在不同皮肤类型中获得了高患者满意度和安全性. Obagi Medical presented new clinical data at the 2025 American Society for Dermatologic Surgery meeting showing its Obagi® saypha® ChIQ™ hyaluronic acid filler performed as well as Juvéderm Voluma® XC in restoring midface volume and improving nasolabial folds, with high patient satisfaction and safety across skin types. 该研究报告是被选定进行口头介绍的前十大摘要之一。 The study was among the top 10 abstracts selected for oral presentation. 临时结果还显示,在使用Obagi Nu-Cil-BioStimTM Scalp Serum 三个月后,头皮健康状况和头发外观有所改善。 Interim results also showed improved scalp health and hair appearance after three months of using Obagi Nu-Cil® BioStim™ Scalp Serum. 该公司引入了评估填充技术的新框架,突出介绍了其MACRO核心技术。 The company introduced a new framework for evaluating filler technologies, highlighting its MACRO Core Technology. Obagi® saypha® ChIQ™正在FDA审核中，而Obagi® saypha® MagIQ™已获批准。 Obagi® saypha® ChIQ™ is under FDA review, while Obagi® saypha® MagIQ™ has received approval.